Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wh...
Cardax reported revenue of $538,946 for fiscal year 2020, down 24.2% from fiscal year 2019, and net income of -$5.06 million. In Q1 2021 (the quarter ended March 31, 2021) revenue was $104,574, down 26.8% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2020.
No profile data available.